Sanofi

SAN

FR0000120578

Pharmaceuticals

Real-time Euronext Paris Other stock markets 10:52:06 2024-04-23 am EDT			5-day change	1st Jan Change
88.61 ^EUR	+0.50%		+2.10%	-1.28%

04:02pm	CAC40: closes in on 8,100, well supported by W-Street	CF
11:02am	CAC40: up slightly after encouraging PMI figures	CF

SANOFI : Gets a Neutral rating from UBS

February 06, 2023 at 06:42 am EST

UBS analyst Michael Leuchten maintains his Neutral opinion on the stock. The target price is unchanged and still at EUR 93.

Latest news about Sanofi

CAC40: closes in on 8,100, well supported by W-Street	10:02am	CF
CAC40: up slightly after encouraging PMI figures	05:02am	CF
Sanofi: positive phase III data in IPT	03:04am	CF
Sanofi Reports Positive Results from Phase 3 Trial of Rilzabrutinib for Immune Thrombocytopenia	01:45am	MT
Sanofi Says Blood-Disorder Drug Meets Key Target in Late-Stage Trial	01:39am	DJ
Sanofi Reaches $100 Million Settlement for US Lawsuits Over Zantac Cancer Claims	01:22am	MT
Sector Update: Health Care Stocks Rise in Monday Afternoon Trading	Apr. 22	MT
European Equities Close Higher in Monday Trading; EC Probes TikTok Over Possible DSA Violations	Apr. 22	MT
Top Midday Stories: Verizon Shares Down, Truist Shares Up Post Earnings; CNH Industrial Names New Chief Executive; Tesla Dissolves Newly Created Marketing Team	Apr. 22	MT
Sanofi to Pay More Than $100 Million to Settle 4,000 Suits Alleging Zantac Causes Cancer	Apr. 22	MT
Sanofi Reportedly Agrees to Settle Zantac Cancer Lawsuits for More Than $100 Million	Apr. 22	MT
SANOFI : Gets a Buy rating from UBS	Apr. 22	ZD
Sector Update: Health Care Stocks Rise Friday Afternoon	Apr. 19	MT
Global markets live: P&G, Amex, Blackstone, Apple, Tesla...	Apr. 19
Sector Update: Health Care Stocks Steady Pre-Bell Friday	Apr. 19	MT
Sector Update: Health Care	Apr. 19	MT
Sanofi Planning to Restructure US Commercial Operations for Vaccines; Job Losses Likely	Apr. 19	MT
Sanofi Reportedly Planning to Restructure US Commercial Operations for Vaccines; Job Losses Likely	Apr. 18	MT
Sanofi to overhaul US operations of vaccines, cut jobs	Apr. 18	RE
European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading	Apr. 18	MT
SANOFI : JP Morgan reiterates its Neutral rating	Apr. 18	ZD
Sanofi Announces Quebec's INESSS Recommends BEYFORTUS® for Prevention of RSV for All Infants 8 Months of Age and Younger	Apr. 18	CI
IGM Biosciences, Sanofi Narrow Partnership to Focus on Potential Immunology and Inflamation Targets	Apr. 17	MT
BeiGene to Award Shares Worth $15 Million to 11 Directors	Apr. 17	MT
Sanofi's Frexalimab Reduces Disease Activity in Multiple Sclerosis Patients in Phase 2 Trial	Apr. 17	MT

Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).

Sector

Pharmaceuticals

Calendar

2024-04-25 - Q1 2024 Earnings Release

Related indices

CAC 40 , EURO STOXX 50 , STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

SANOFI : Looking beyond the quarterly miss, Sanofi remains an attractive bet

February 01, 2024 at 11:26 am EST

Sanofi Sees Trend for Years of Steady Growth: CFO

February 03, 2023 at 03:56 pm EST

More Strategies

Ratings for Sanofi

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

88.17 EUR

Average target price

107.5 EUR

Spread / Average Target

+21.92%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SANOFI	-1.28%	117B
ELI LILLY AND COMPANY	+26.73%	659B
NOVO NORDISK A/S	+26.94%	557B
JOHNSON & JOHNSON	-5.19%	359B
MERCK & CO., INC.	+16.64%	322B
ABBVIE INC.	+9.44%	297B
ASTRAZENECA PLC	+6.06%	215B
NOVARTIS AG	+5.26%	210B
ROCHE HOLDING AG	-6.01%	200B
PFIZER, INC.	-8.53%	149B

Other Pharmaceuticals

Sanofi

Equities

SAN

FR0000120578

Pharmaceuticals

SANOFI : Gets a Neutral rating from UBS

Latest news about Sanofi

Chart Sanofi

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Sanofi

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals